Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05964504 · ClinicalTrials.gov registry record
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
A clinical trial of Metastatic Breast Cancer and Lobular Breast Carcinoma, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 12
- Enrollment target
- 4
- Study locations
NCT05964504 is a study of Metastatic Breast Cancer and Lobular Breast Carcinoma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 12 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05964504, a study of Metastatic Breast Cancer and Lobular Breast Carcinoma, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Conditions Studied
Interventions
- PROCEDURE Blood Specimen
Study Locations (4)
California
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Pennsylvania
- Abramson Cancer Center - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2036-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05964504
The ClinicalTrials.gov registry entry for NCT05964504 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood Specimen is the first listed.
NCT05964504 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT05964504 about?
NCT05964504 is a clinical study titled "Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)". This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
What is the current status of trial NCT05964504?
This trial is currently recruiting. The enrollment target is 12 participants. The study started on 2023-12-20. Estimated completion is 2036-02-28.
What conditions does trial NCT05964504 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Lobular Breast Carcinoma.
What interventions are being tested in trial NCT05964504?
The interventions under investigation include: Blood Specimen (PROCEDURE).
Who is sponsoring clinical trial NCT05964504?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05964504 being conducted?
This trial has 4 study locations across California, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
RECRUITING · NA
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.